Revalesio Presents Additional Analyses from the Phase 2 RESCUE Clinical Trial for RNS60 in Acute Ischemic Stroke

Revalesio Presents Additional Analyses from the Phase 2 RESCUE Clinical Trial for RNS60 in Acute Ischemic Stroke

TACOMA, Wash., May 21, 2025 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced data from a post hoc analysis of its completed Phase 2 RESCUE clinical trial, showing that ischemic stroke…

Presidential Symposium Award & Large Clinical Studies

.flex_column.av-pxfofs-f8cffa300d0abe60229a0238b37e998b{ border-radius:0px 0px 0px 0px; padding:0px 0px 0px 0px; } 22/05/2025/in ESO, ESOC, Stroke Research /by Stefania De Vito Session Report: Presidential Symposium Award & Large Clinical Studies Author: Dr. Ellis van Etten At this year’s Presidential Symposium Award & Large Clinical Studies session, the presentations demonstrated the evolving landscape of stroke research. With studies ranging f…